Johnson & Johnson agreed to acquire Intra-Cellular Therapies, a company focused on treatments for central nervous system disorders, for about $14.6 billion. Katie Greifeld reports on “Bloomberg Open Interest.”
J&J to Buy Intra-Cellular for About $14 Billion
Estimated read time
1 min read
You May Also Like
LA Wildfire Insurance-Loss Estimates Approach $40 Billion
January 14, 2025
How Israel erased a town of 200,000
January 14, 2025
+ There are no comments
Add yours